Last reviewed · How we verify
Non-steroidal aromatase inhibitor therapy
Non-steroidal aromatase inhibitor therapy is a Aromatase inhibitor Small molecule drug developed by Amgen. It is currently in Phase 3 development for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic setting).
A non-steroidal aromatase inhibitor blocks the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer.
A non-steroidal aromatase inhibitor blocks the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic setting).
At a glance
| Generic name | Non-steroidal aromatase inhibitor therapy |
|---|---|
| Sponsor | Amgen |
| Drug class | Aromatase inhibitor |
| Target | Aromatase (CYP19A1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Aromatase inhibitors (AIs) work by inhibiting the aromatase enzyme, which converts androgens to estrogen in postmenopausal women. By reducing circulating estrogen levels, these agents deprive estrogen receptor-positive breast cancer cells of the hormonal stimulus needed for growth and proliferation. Non-steroidal AIs are reversible competitive inhibitors of aromatase, distinguishing them from steroidal AIs.
Approved indications
- Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic setting)
Common side effects
- Hot flashes
- Arthralgia/joint pain
- Fatigue
- Headache
- Vaginal dryness
- Osteoporosis/bone loss
- Elevated cholesterol
Key clinical trials
- Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (PHASE2)
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (PHASE3)
- A Study of Single Dose of BL0175 in Postmenopausal Women (PHASE1)
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (PHASE2)
- PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (PHASE3)
- Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PHASE2)
- Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (PHASE3)
- Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-steroidal aromatase inhibitor therapy CI brief — competitive landscape report
- Non-steroidal aromatase inhibitor therapy updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Non-steroidal aromatase inhibitor therapy
What is Non-steroidal aromatase inhibitor therapy?
How does Non-steroidal aromatase inhibitor therapy work?
What is Non-steroidal aromatase inhibitor therapy used for?
Who makes Non-steroidal aromatase inhibitor therapy?
What drug class is Non-steroidal aromatase inhibitor therapy in?
What development phase is Non-steroidal aromatase inhibitor therapy in?
What are the side effects of Non-steroidal aromatase inhibitor therapy?
What does Non-steroidal aromatase inhibitor therapy target?
Related
- Drug class: All Aromatase inhibitor drugs
- Target: All drugs targeting Aromatase (CYP19A1)
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic setting)
- Compare: Non-steroidal aromatase inhibitor therapy vs similar drugs
- Pricing: Non-steroidal aromatase inhibitor therapy cost, discount & access